Merck KGaA (FRA:MRK) Rating Reiterated by DZ Bank

DZ Bank reiterated their buy rating on shares of Merck KGaA (FRA:MRK) in a research report report published on Wednesday morning, Borsen Zeitung reports.

A number of other research firms have also issued reports on MRK. Warburg Research set a €103.00 ($119.77) target price on Merck KGaA and gave the company a neutral rating in a report on Tuesday, July 30th. Sanford C. Bernstein set a €108.00 ($125.58) target price on Merck KGaA and gave the company a neutral rating in a report on Friday, August 9th. Credit Suisse Group set a €110.00 ($127.91) target price on Merck KGaA and gave the company a buy rating in a report on Thursday, August 8th. Morgan Stanley set a €96.00 ($111.63) target price on Merck KGaA and gave the company a neutral rating in a report on Tuesday, June 18th. Finally, UBS Group set a €99.00 ($115.12) target price on Merck KGaA and gave the company a neutral rating in a report on Thursday, August 8th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average target price of €100.67 ($117.05).

Shares of FRA:MRK traded down €0.38 ($0.44) during trading on Wednesday, reaching €92.96 ($108.09). The company had a trading volume of 295,845 shares. The firm’s fifty day moving average price is €93.68. Merck KGaA has a fifty-two week low of €76.60 ($89.07) and a fifty-two week high of €115.00 ($133.72).



Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

See Also: P/E Growth (PEG)

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.